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Indomethacin induces apoptosis via a MRP1-dependent
mechanism in doxorubicin-resistant small-cell lung cancer cells
overexpressing MRP1
DJA de Groot1, M van der Deen1, TKP Le1, A Regeling1, S de Jong1 and EGE de Vries*,1
1Department of Medical Oncology, University of Groningen and University Medical Center, PO Box 30.001, 9700 RB, Groningen, The Netherlands
Small-cell lung cancers (SCLCs) initially respond to chemotherapy, but are often resistant at recurrence. The non-steroidal
anti-inflammatory drug indomethacin is an inhibitor of multidrug resistance protein 1 (MRP1) function. The doxorubicin-resistant
MRP1-overexpressing human SCLC cell line GLC4-Adr was highly sensitive for indomethacin compared with the parental
doxorubicin-sensitive line GLC4. The purpose of this study was to analyse the relationship between hypersensitivity to indomethacin
and MRP1 overexpression. The experimental design involved analysis of the effect of MRP1 downregulation on indomethacin-
induced cell survival and apoptosis in GLC4-Adr and GLC4, using siRNA. In addition the effect of indomethacin on glutathione levels
and mitochondrial membrane potential was investigated. Small interfering RNAs directed against MRP1 reduced MRP1 mRNA levels
twofold and reduced efflux pump function of MRP1, which was reflected by a 1.8-fold higher accumulation of MRP1 substrate
carboxyfluorescein, in si-MRP1 versus si-Luciferase-transfected GLC4-Adr cells. Multidrug resistance protein 1 downregulation
decreased initial high apoptosis levels 2-fold in GLC4-Adr after indomethacin treatment for 24 h, and increased cell survival (IC50)
from 22.8±2.6 to 30.4±5.1mM following continuous indomethacin exposure. Multidrug resistance protein 1 downregulation had no
effect on apoptosis in GLC4 or on glutathione levels in both lines. Although indomethacin (20mM) for 2 h decreased glutathione levels
by 31.5% in GLC4-Adr, complete depletion of cellular glutathione by L-buthionine (S,R)-sulphoximine only resulted in a small increase
in indomethacin-induced apoptosis in GLC4-Adr, demonstrating that a reduced cellular glutathione level is not the primary cause of
indomethacin-induced apoptosis. Indomethacin exposure decreased mitochondrial membrane potential in GLC4-Adr cells, suggesting
activation of the mitochondrial apoptosis pathway. Indomethacin induces apoptosis in a doxorubicin-resistant SCLC cell line through
an MRP1-dependent mechanism. This may have implications for the treatment of patients with MRP1-overexpressing tumours.
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Lung cancer is the tumour type with the highest incidence in males
in the Western world, and its incidence in females is rising. Small-
cell lung cancer (SCLC) represents about 25% of all lung cancers.
Small-cell lung cancers are well known for their initial sensitivity
to chemotherapeutic agents. However, they frequently recur, and it
is at this time that the tumours become drug resistant (Glisson,
2003). Common mechanisms of drug resistance are the over-
expression of drug transporters and the resistance to apoptosis
induction in tumour cells. The ATP-binding cassette (ABC) family
of transport proteins is the major family of drug transporters. The
multidrug resistance protein 1 (MRP1), a member of the ABC
family of drug transporters, can act as an efflux pump for a
number of chemically unrelated agents. Intracellular glutathione
(GSH) can be conjugated to these agents by glutathione-
S-transferase. Multidrug resistance protein 1 transports GSH, GSH
conjugates and unconjugated cytotoxic drugs to the extracellular
compartment (Cole et al, 1994; Mu¨ller et al, 1994; Zaman et al,
1994; Paul et al, 1996; Ballatori et al, 2005). Glutathione is required
for several other cellular functions such as protein and DNA
synthesis, cell cycle regulation, protection against oxidative damage
and detoxification of toxins (Wang and Ballatori, 1998).
The non-steroidal anti-inflammatory drug indomethacin is a
well-known inhibitor of MRP1 function. It inhibits glutathione-S-
transferase and also functions as a direct substrate for MRP1
(Draper et al, 1997; Touhey et al, 2002). In addition, in low
concentrations indomethacin can increase GSH efflux (Evers et al,
2000). We previously reported that exposure of the MRP1-
overexpressing doxorubicin-resistant SCLC cell line GLC4-Adr to
indomethacin resulted in caspase-8- and caspase-9-dependent
apoptosis induction, suggesting the involvement of the extrinsic
and intrinsic apoptosis pathways. In contrast, exposure of the
parental cell line GLC4 to indomethacin did not induce apoptosis
(De Groot et al, 2005). Indomethacin as well as MK571 increase
doxorubicin sensitivity in these GLC4 cell lines. The use of this
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isogenic model implies that factors rendering GLC4-Adr
resistant to doxorubicin are very likely also be responsible for
indomethacin sensitivity. Studies investigating the increase in
drug sensitivity after indomethacin exposure in human and
murine cell lines showed that the drug-sensitizing effect of
indomethacin was not prostaglandin dependent, but was depen-
dent on glutathione-S-transferase, or caused by direct inhibition of
glutathione-S-transferase (Draper et al, 1997). Insight into this
mechanism might result in a simple, relatively non-toxic way to
exploit MRP1 overexpression for apoptosis induction in chemo-
therapy-resistant cells. In this study, we therefore investigated
whether indomethacin-induced apoptosis is related to MRP1
overexpression. In addition the mechanism of indomethacin-




The GLC4 cell line was derived from a pleural effusion in our
laboratory and kept in culture in RPMI 1640 medium supplemen-
ted with 10% heat-inactivated foetal calf serum (FCS) (both from
Life Technologies, Breda, The Netherlands). The GLC4-Adr sub-
line acquired resistance not only to doxorubicin but also to a wide
range of other chemotherapeutic agents, by stepwise increases in
doxorubicin concentrations in the culture medium (Zijlstra et al,
1987; De Jong et al, 1990; Meijer et al, 1991; Mu¨ller et al, 1994).
GLC4-Adr is 190.6±16.2-fold more resistant to doxorubicin than
GLC4. The doxorubicin resistance in GLC4-Adr is due to a
downregulation of the activity of DNA-topoisomerase II (TOPO
II) and amplification and consequent 79-fold overexpression of the
MRP1 gene. GLC4-Adr was maintained in culture medium 1.2mM
doxorubicin twice weekly. GLC4-Adr was cultured without
doxorubicin for 20 days before experiments. Cells were cultured
at 371C in a humidified atmosphere with 5% CO2. Cells from
exponentially growing cultures were used for all experiments.
Forty-eight hours of indomethacin (50mM) treatment induces
50.6±14.6% apoptosis in GLC4-Adr and 2.1±1.5% apoptosis
in GLC4.
Chemicals, media and reagents
HAM/F12 and DMEM medium (minimal essential medium (MEM,
supplemented with Earle’s salts and L-glutamine), oligofectamine,
RPMI 1640, phosphate-buffered saline (PBS), Hoechst 33258,
MitoTracker Red CM-H2XRos and Trizol were purchased from
Invitrogen Life Technologies (Breda, The Netherlands)). Carboxy-
fluorescein diacetate (CFDA), 3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyltetrazolium bromide (MTT), L-buthionine (S,R)-sulphoximine
(BSO), glutathione reductase, nicotinamide adenine dinucleotide
phosphate (NADPH), trichloric acid (TCA), GSH, 5,50-dithio-
bis(2-nitrobenzoic acid) (DTNB) and propidium iodide (PI) were
obtained from Sigma-Aldrich BV (Zwijndrecht, The Netherlands);
DNase-I was from Roche Diagnostics (Mannheim, Germany),
doxorubicin-HCl from Pharmachemie BV (Haarlem, The Nether-
lands), ethylenedinitrilo tetraacetic acid disodiumsalt dihydrate
(EDTA) from Merck (Darmstadt, Germany). MK571 was pur-
chased from Omnilabo (Breda, The Netherlands), the qPCR core
kit from Eurogentec (Seraing, Belgium), the RNeasy kit from
Qiagen (Venlo, The Netherlands) and Vitrogen from Nutacon
(Leimuiden, The Netherlands).
Flow cytometric detection of MRP1 activity
To determine MRP1 activity, cells were incubated with 0.1mM
carboxyfluorescein diacetate as described previously (Van der
Kolk et al, 1998), with slight modifications. Carboxyfluorescein
diacetate is converted intracellularly to carboxyfluorescein (CF),
which is a fluorescent MRP1 substrate. To establish the effect of
indomethacin on the activity of MRP1, 1 106 cells were incubated
in 0.5 ml RPMI 1640 medium (371C, 5% CO2, 1 h) with CFDA.
MK571 (50 mM) served as a positive control for the inhibition of
MRP1 activity. Cells were pelleted for 15 s at 12 000 g and
resuspended in 350 ml ice-cold RPMI medium with 0.1mg ml1 PI
to distinguish dead cells from living cells. Fluorescence of CF was
analysed with a FACS Caliber flow cytometer (BD Biosciences,
San Jose, CA, USA). A total of 10 000 events were measured per
sample. The Winlist 5.1 programme (Verity Software House Inc.,
Topsham, ME, USA) was used to calculate mean fluorescence
intensity (MFI) values. The efflux-blocking factor (BF) was defined
as the ratio between MFI of substrate plus modulator and MFI of
substrate. All measurements were corrected for the negative
control (without indomethacin). Experiments were performed in
triplicate.
RNA interference
To explore the role of MRP1 in indomethacin-induced apoptosis,
siRNAs directed against MRP1 (si-MRP1) and luciferase
(si-Luciferase, negative control) were purchased from Eurogentec
(Maastricht, The Netherlands). The sense sequence for si-MRP1
was 50-GGAGUGGAACCCCUCUCUG-30 and the antisense
sequence was 50-CAGAGAGGGGUUCCACUCC-30. For si-Luciferase,
the sense sequence was 50-CUUACGCUGAGUACUUCGA-30 and the
antisense sequence was 50-UCGAAGUACUCAGCGUAAG-30.
GLC4 and GLC4-Adr cells were seeded in six-wells plates at a
concentration of 3 105 well1. The next day, transfection was
performed using 200 nM oligonucleotides with Oligofectamine and
RPMI 1640, in the absence of FCS according to the manufacturer’s
instructions. After 4 h the medium containing FCS was added to an
FCS solution of final concentration of 10%. Multidrug resistance
protein 1 function assays with flow cytometre and RNA extraction
were carried out 48 h after siRNA transfection.
RNA isolation and quantitative RT–PCR
Cells treated with siRNA for 48 h were washed with ice-cold PBS
and resuspended in 1 ml of Trizol. After 5 min incubation at room
temperature, the lysate was stored at 801C until use. RNA was
isolated according to standard manufacturer’s protocols, followed
by a DNase-I treatment. For RNA purification, the RNeasy kit was
used following standard procedures. RNA (800 ng) was subjected
to a complementary DNA (cDNA) synthesis reaction.
Quantitative reverse transcriptase –polymerase chain reaction
(RT–PCR) was performed using the ABI PRISM 7700 sequence
detector (Applied Biosystems, Foster City, USA, USA) as described
previously (Ros et al, 2003). In brief, a qPCR core kit was used and
the PCR mixture contained 900 nM of sense and antisense primers,
200 nM of fluorogenic probe (labelled by a 50 FAM reporter and a 30
TAMRA quencher). Each sample was analysed in duplicate. Primer
sequences for MRP1 were as follows: for the sense strand, 50-GGTG
GGCCGAGTGGAATT-30; for the antisense strand, 50-TTGATGTGC
CTGAGAACGAAGT-30 and for the probe strand, 50FAM-CTGCCT
GCGCTACCGAGAGGACCT-TAMRA30. Primer sequences for the
housekeeping gene GAPDH were for the sense strand 50-GGTGGT
CTCCTCTGACTTCAACA-30, for the anti-sense strand 50-GTGGTC
GTTGAGGGCAATG-30 and for the probe strand 50FAM-ACACCC
ACTCCTCCACCTTTGACGC-TAMRA30. Cycle numbers at which
the sample fluorescence signal increases above a fixed threshold
level (Ct value) correlate inversely with mRNA levels.
MTT assay
The cell lines were cultured in HAM/F12 and DMEM medium
(1 : 1) supplemented with 20% FCS. The effect of doxorubicin and
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indomethacin on survival was tested in an MTT assay as described
previously (Timmer-Bosscha et al, 1989). Cells were incubated
with a range of indomethacin concentrations for 4 days at 371C
and 5% CO2 in a humidified environment. The effect of si-MRP1
downregulation on cell survival was tested in the MTT assay
using continuous incubation with indomethacin. After a 4-day
culture period, MTT (5 mg ml1 in PBS) was added and formazan
crystal production was measured as described previously. Controls
consisted of media without cells (background extinction) and cells
incubated with medium instead of the cytotoxic agent. Experi-
ments were performed three times in quadruplicate.
Apoptosis assay
The effect of GSH on indomethacin-mediated apoptosis induction
was tested in cells (1.5 104 well1) cultured in 96-wells plates and
preincubated with 250 mM BSO for 24 h. Apoptosis was induced by
adding different concentrations of indomethacin for 24 h.
In addition, GLC4-Adr cells were transfected with si-MRP1 and
si-Luciferase. After 48 h these cells were plated in 96-wells plates
and exposed to different concentrations of indomethacin for 24 h.
Acridine orange staining (10mg ml1) was used to identify
apoptotic cells. Apoptosis was defined as the appearance of
apoptotic bodies and/or chromatin condensation, viewed using a
fluorescence microscope. Results were expressed as the percentage
of apoptotic cells in a culture by counting at least 200 cells per well.
All apoptosis assays were performed in duplicate and repeated
three times.
Glutathione assay
Free GSH was measured by a modified method as described by
Allen et al (2000). Cells were plated in 25-cm2 flasks and exposed
to 250 mM BSO for 24 h to achieve adequate GSH depletion. Cells
were exposed to indomethacin and 50 mM MK571 for 2 h to evaluate
short-term effect of these drugs on GSH levels. Cells were isolated
from six-well plates and washed in PBS. Protein was precipitated
with 5% TCA and the precipitate was spun down at 4500 g. The
supernatant was diluted to 1 mg ml1 protein. A 150-ml volume of
the supernatant was put in a 96-well plate in different dilutions.
Ellman’s reagents (12 mM DTNB, 5 mM EDTA in 125 mM phosphate
buffer) and 10 ml of 125 mM phosphate buffer containing 5 mM
EDTA and 0.4 U of glutathione reductase were added to the
samples. The reaction was started by the addition of 20 ml 5.6 mM
NADPH in 125 mM phosphate buffer containing 5 mM EDTA. 5,50-
Dithio-bis(2-nitrobenzoic acid reduction produced in the assay
was measured at 405 nm. All GSH assays were performed three
times.
Mitochondrial membrane potential
To determine whether there is an absolute decrease in fluores-
cence, 3 105 cells were seeded in six-well plates and exposed to
different concentrations of indomethacin for 24 h. MitoTracker
reds (300 nM) was added for 45 min at 371C and cells were
analysed with an Elite flow cytometer (Bechman Coulter, Fullerton,
CA, USA). MitoTracker red fluorescence was measured in the PE
channel. Experiments were performed three times and a repre-
sentative example was shown.
Statistical analysis
Paired Student’s t-test, independent samples t-test or one-sample
t-test was used to calculate statistical differences. Differences were
considered significant when Po0.05.
RESULTS
The effect of MRP1 downregulation on
indomethacin-induced apoptosis and cell death
Compared with the parental cell line GLC4, the doxorubicin-
resistant sub-line GLC4-Adr strongly overexpresses MRP1 and is
highly sensitive to indomethacin (De Groot et al, 2005). The role of
MRP1 in indomethacin sensitivity was investigated using an MRP1
siRNA approach. Efficient downregulation of MRP1 mRNA was
demonstrated, since the relative MRP1 mRNA expression levels, as
determined with quantitative RT–PCR, were reduced to
55.2±18.3% in si-MRP1-transfected GLC4-Adr cells, and to
44.9±1.1% in si-MRP1-transfected GLC4 compared with their
respective si-Luciferase-transfected controls. The absolute MRP1
mRNA expression levels, however, were 79 times higher in
GLC4-Adr compared with GLC4 cells.
The CF accumulation following 1 h CFDA exposure was used to
determine the MRP1 function in siRNA-transfected GLC4-Adr
cells. Carboxyfluorescein accumulation was 84±19% higher in the
si-MRP1-transfected cells compared with the si-Luciferase-
transfected cells, indicating that the MRP1 function in GLC4-Adr
was indeed decreased as a result of MRP1 mRNA downregulation
(Figure 1).
Indomethacin-induced apoptosis was clearly reduced in si-
MRP1-transfected GLC4-Adr cells (Figure 2). For example, a
reduction in apoptosis (2.0±0.05-fold) was observed at 75mM
indomethacin. At higher indomethacin concentrations, similar
reductions were observed in si-MRP1-transfected GLC4-Adr cells
compared with si-Luciferase-transfected GLC4-Adr cells. However,
indomethacin concentrations up to 150 mM did not induce
apoptosis in either si-MRP1- or si-Luciferase-transfected GLC4
cells (data not shown).
Apart from a reduction in apoptosis, an increased survival
following indomethacin exposure was also observed in si-MRP1-
transfected GLC4-Adr cells (Figure 3). The IC50 for indomethacin
was 22.8±2.6 mM in si-Luciferase-transfected GLC4-Adr and
30.4±5.1 mM in si-MRP1-transfected GLC4-Adr (Po0.05). No























Figure 1 Relative cellular CF fluorescence after si-MRP1 and si-
Luciferase treatment (*Po0.05).
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cells transfected with si-Luciferase or si-MRP1 for indomethacin
concentrations up to 100 mM.
Effect of indomethacin on GSH levels
To investigate whether the protective effect of MRP1 siRNA against
indomethacin-induced apoptosis is not only related to a reduction
in MRP1 activity but also to an effect on cellular GSH levels, we
measured intracellular GSH concentrations. GLC4 cells have a
slightly lower although not significant GSH content of
9.9±2.2 mg mg of total cellular protein compared with GLC4-Adr
cells with a cellular GSH content of 11.1±6.1 mg mg1 (P¼ 0.75).
Interfering with the MRP1 function did not affect cellular GSH
levels in either cell line. First, downregulation of MRP1 with si-
MRP1 transfection did not alter intracellular GSH content in GLC4
and GLC4-Adr. Second, when cells were exposed to 50 mM of the
specific MRP1 inhibitor MK571 for 2 h, GSH levels were not
affected and no apoptosis was induced. Higher concentrations of
MK571 up to 100 mM did induce apoptosis (data not shown).
Indomethacin exposure alone, however, lowered GSH levels by
31.5±19.8% in GLC4-Adr cells (Po0.05) and by 20.6±37.7% in
GLC4 cells (P¼ 0.28) (Figure 3).
To confirm the relationship between GSH levels and indo-
methacin-induced apoptosis, cellular GSH levels in both cell lines
were reduced with BSO treatment. As shown in Figure 4, GSH
levels were diminished after BSO treatment in GLC4-Adr cells. This
resulted in an increase in apoptosis levels in GLC4-Adr cells treated
with indomethacin in combination with BSO compared with GLC4-
Adr cells treated with indomethacin only, for example, from 14.1 to
35.8% apoptosis at 25 mM indomethacin (Figure 5). However, at
higher indomethacin concentrations, the relative increase in
apoptosis was less pronounced. Indomethacin in combination
with BSO did not induce apoptosis in GLC4 at any of these
concentrations.
These results indicate that cellular GSH levels are not primary
determinants for MRP1-independent indomethacin-induced apop-
tosis, since GSH depletion did not result in indomethacin-induced
apoptosis in GLC4 cells. Furthermore, it suggests that at relatively
low indomethacin concentrations GSH levels may be determinants
of indomethacin-induced apoptosis in an MRP1-dependent
manner.
Indomethacin-induced loss of mitochondrial membrane
potential
Previously, we have demonstrated that indomethacin-induced
apoptosis in GLC4-Adr was caused by caspase-8 as well as caspase-
9 activation (De Groot et al, 2005). However, the role of
mitochondria in indomethacin-induced apoptosis in GLC4-Adr
was not established. Therefore, we determined whether indo-
methacin-mediated apoptosis induction coincided with loss of
mitochondrial membrane potential in the cells. Flow cytometry
revealed that after indomethacin exposure for 24 h two GLC4-Adr
cell populations exist, a MitoTracker red-high and a MitoTracker
red-low population (Figure 6). The presence of the MitoTracker
red-low population (40.8% at 150mM of indomethacin) at 24 h
suggests that loss of mitochondrial membrane potential in GLC4-
Adr occurs in conjunction with apoptosis induction, as at 100mM
indomethacin, up to 84.6% of apoptosis was induced. Indometha-
cin had no effect on mitochondrial membrane potential in GLC4
(Figure 6).
DISCUSSION
This is the first study demonstrating that indomethacin can induce
apoptosis via an MRP1-dependent mechanism in the MRP1-
































Figure 3 Indomethacin-induced growth inhibition. Survival of GLC4 and
GLC4-Adr cells 48 h after si-Luciferase (triangle) or si-MRP1 (square)





















Figure 2 Indomethacin-induced apoptosis in GLC4-Adr 48 h after si-
Luciferase transfection (white) or si-MRP1 transfection (grey). Cells were
exposed to indomethacin for 24 h. No apoptosis was observed in GLC4
(data not shown). Data represent the mean±s.d. of three independent
experiments (*Po0.05).
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downregulation of MRP1, as shown using the elevated cellular level
of the MRP1 substrate CF, resulted in less apoptosis and
concomitantly in enhanced survival of GLC4-Adr cells following
indomethacin exposure. In contrast, MRP1 downregulation in
GLC4 cells had no effect on indomethacin-induced apoptosis or
survival. Glutathione levels in GLC4-Adr cells were decreased
following indomethacin exposure, but these levels were not
affected by MRP1 downregulation. In addition, depletion of
cellular GSH by BSO made GLC4-Adr cells more sensitive to
indomethacin. Since GSH depletion by BSO did not enhance
indomethacin-induced apoptosis in GLC4, our results suggest that
indomethacin induces apoptosis via an MRP1-dependent mechan-
ism, which may partially be dependent on cellular GSH levels.
Another MRP1-dependent mechanism involved is the indomethacin-
induced activation of the mitochondrial apoptosis pathway, which
is reflected in loss of the mitochondrial membrane potential
simultaneously with apoptosis induction in GLC4-Adr. These
results confirm our previous finding that indomethacin induces
apoptosis via activation of caspase-8 as well as caspase-9 in GLC4-
Adr (De Groot et al, 2005).
Indomethacin is a well-known inhibitor of glutathione-S-
transferase and cyclooxygenase, but it can also affect MRP1
(Draper et al, 1997; Roller et al, 1999). Indomethacin increases
chemotherapy sensitivity through inhibition of MRP1 function and
stimulation of the GSH efflux in MRP1-overexpressing cell lines, as
demonstrated in polarized Madin– Darby canine kidney (MDCKII)
cells (Evers et al, 2000). Drug-induced GSH efflux through MRP1
has been described for verapamil in baby hamster kidney-21 cells
transfected with human MRP1 (Trompier et al, 2004). The GSH
levels in GLC4 and GLC4-Adr are similar, but GSH turnover is
much higher in GLC4-Adr due to its increased MRP1 expression
(Kool et al, 1997). In the present study, we demonstrated that GSH
levels in GLC4-Adr did not rise after 2 h exposure to indomethacin.
In contrast, GSH levels were even slightly decreased in GLC4-Adr
but not in GLC4, suggesting that indomethacin-associated MRP1
inhibition does not cause indomethacin-induced apoptosis.
NSAIDs including indomethacin can be metabolized intra-
cellularly generating reactive oxygen species (ROS). The formation
of ROS has actually been implicated in indomethacin idiosyncratic
toxicity such as bone marrow toxicity or hepatitis (Galati et al,
2002). ROS are inactivated by mitochondrial GSH. In our model,
cellular GSH levels were decreased by short exposure to
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Figure 4 Relative GSH levels in GLC4 and GLC4-Adr cells. Glutathione intracellular concentration was determined after 24 h BSO, 2 h MK571 or 2 h
indomethacin exposure. Glutathione levels were calculated as the relative concentration compared with untreated cells. Data represent the mean±s.d. of
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Figure 5 Indomethacin-induced apoptosis in GLC4 (A) and GLC4-Adr
(B) after 24 h BSO exposure (grey), or control (white). Cells were
exposed to indomethacin for 24 h. No apoptosis was observed in GLC4.
Data represent the mean±s.d. of three independent experiments
(*Po0.05).
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drug that specifically inhibits GSH production, increases indo-
methacin-mediated apoptosis in GLC4-Adr but not in GLC4. A
reduction in cellular GSH level can be an important trigger for
apoptosis induction as demonstrated in the B-cell lymphoma cell
line PW after exposure to BSO (Armstrong et al, 2002). Cellular
GSH depletion also resulted in apoptosis in a caspase-8-dependent
manner in NCI-H889 SCLC cells, following treatment with the
proteasome inhibitor MG132 (Bang et al, 2004). In addition,
mitochondria of GSH-depleted cells can become more sensitive to
oxidative stress (Henry-Mowatt et al, 2004). Oxidative stress then
resulted in the loss of mitochondrial membrane potential and the
release of several essential players of the mitochondrial apoptosis
pathway, such as cytochrome c and apoptosis-inducing factor into
the cytosol as well as the activation of caspases and apoptotic
protease-activating factor-1 (Kannan and Jain, 2000; Henry-
Mowatt et al, 2004). Previously, we have shown that inhibition of
active caspase-9 decreased indomethacin-induced apoptosis in
GLC4-Adr cells by 44%, suggesting the involvement of the
mitochondrial apoptosis pathway (De Groot et al, 2005). In the
present study, we demonstrated that indomethacin actually causes
loss of mitochondrial membrane potential and subsequently
results in the activation of the mitochondrial apoptosis pathway
in GLC4-Adr cells. Further research is needed to establish the role
of oxidative stress in the loss of the mitochondrial potential. Taken
together our results indicate that indomethacin-induced apoptosis
in GLC4-Adr cells is dependent on MRP1 expression. Indometha-
cin-induced apoptosis is accompanied by loss of mitochondrial
membrane potential. Activation of this pathway may be further
enhanced by caspase-8 activation and Bid cleavage, which we have
reported earlier for indomethacin-treated GLC4-Adr cells (De
Groot et al, 2005).
Downregulation of MRP1 and concomitant loss of MRP1
function slightly decreased indomethacin sensitivity indicating
that MRP1 activity facilitates indomethacin-mediated apoptosis.
However, one has to take in account that the MRP1 down-
regulation was not complete, so the effect of MRP1 activity on
indomethacin-induced apoptosis is probably underestimated in
this model. In addition, GSH depletion by BSO increases
indomethacin-mediated apoptosis in GLC4-Adr only. These two
findings indicate that the MRP1 function is important in
indomethacin-induced apoptosis. The exploitation of a chemother-
apy resistance factor such as MRP1 to induce apoptosis is a novel
and potentially interesting finding.
In the future, identification of MRP1-overexpressing tumours
and exposure of these tumours to combination therapies including
indomethacin may provide a novel approach in the treatment of
MRP1-overexpressing cancers.
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Figure 6 Flow cytometric analysis of intact mitochondria in GLC4 and GLC4-Adr cells after 24 h exposure to indomethacin and stained with MitoTracker
red. Cells not exposed to indomethacin were compared with cells exposed to 150 mM indomethacin. A representative example is shown.
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